Pacific Biosciences of California, Inc. is an American biotechnology company specializing in genetic sequencing. Based in Menlo Park, California, and known commercially as PacBio, it designs instruments, consumables, and software for DNA analysis. Its positioning is primarily built around long reads: rather than reconstructing a genome from very short fragments, this approach makes it possible to observe longer sequences and shed light on certain regions that are difficult to interpret.
A company rooted in single-molecule research
Founded in 2004 and publicly listed in 2010, Pacific Biosciences was built around SMRT technology, which stands for Single Molecule, Real-Time. This technology observes in real time the incorporation of nucleotides by an enzyme that copies DNA. The first commercial system, PacBio RS, paved the way for several generations of platforms, including the Sequel and later Revio families.
This trajectory reflects the evolving needs of genomics. Beyond reading DNA bases, researchers seek to identify structural variations, distinguish the copies inherited from each parent, and assemble more complete reference genomes. Long reads provide information that complements the data obtained using short-read sequencing technologies.
Instruments and a genomic analysis workflow
HiFi technology is a central component of PacBio’s offering. It combines the length of the fragments analyzed with repeated readings of the same molecule to produce a highly accurate consensus sequence. This method notably helps resolve repetitive regions and detect variations that other approaches may characterize less effectively.
Applications span research into rare diseases, cancer, microbiology, agriculture, and biodiversity. Transcript sequencing also makes it possible to study the different forms of RNA produced by a gene. Certain protocols provide access to epigenetic information, particularly DNA methylation, extending beyond the sequence of bases alone.
The business model combines platform sales, the supply of consumables, and services. The software offering transforms raw data into usable results. Users include sequencing centers, academic institutions, and organizations involved in biomedical research. Clinical applications, however, require validation and regulatory frameworks specific to each use.
What next?
For PacBio, the challenge is to make long reads more accessible and easier to integrate into laboratory practices. The overall cost of analyses, instrument throughput, sample preparation, and computing capabilities remain decisive factors in adoption.
In a competitive market, its development will also depend on demonstrating a tangible benefit over established methods. Translational research, complex genomes, and the detailed characterization of genetic variations represent potential areas for expansion, without guaranteeing a wholesale replacement of short reads.